Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High Risk Myelodysplastic Syndrome

A phase I-II study of bendamustine fractionated twice daily schedule for 4 days identified 75 mg/m(2) intravenously (IV) twice daily for 4 days as a phase II study schedule. BACKGROUND: Alkylating agents have shown activity in leukemia. Bendamustine, an active alkylating agent in lymphoma and chroni...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Chacar, Christelle, Jabbour, Elias, Ravandi, Farhad, Borthakur, Gautam, Kadia, Tapan, Estrov, Zeev, Rios, Mary Beth, Cortes, Jorge, Kantarjian, Hagop
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4050633/
https://ncbi.nlm.nih.gov/pubmed/22578814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.03.004
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia